- Senior Clinician, Clinical Trials Core
Julie E. Ledgerwood, D.O., is a vaccine clinical researcher and serves as chief of the Clinical Trials Program. She is also a principal investigator for Phase I and II vaccine clinical trials at the VRC, studying the safety and immunogenicity of vaccines and monoclonal antibodies targeting HIV, influenza, Ebola, malaria, and other emerging infectious diseases. After completing a residency in internal medicine at Johns Hopkins Bayview Medical Center in Baltimore in 2002, Dr. Ledgerwood joined NIAID as a clinical fellow in allergy and immunology. In 2003, she joined the VRC as a clinical investigator. Dr. Ledgerwood is board-certified in allergy and immunology by the American Board of Allergy and Immunology and board- certified in internal medicine by the American Board of Internal Medicine. She is a graduate of Phillips University and the Oklahoma State University Center for Health Sciences, College of Osteopathic Medicine.
- (2015). Chimpanzee Adenovirus Vector Ebola Vaccine - Preliminary Report. NEW ENGLAND JOURNAL OF MEDICINE.
- (2020). Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. NEW ENGLAND JOURNAL OF MEDICINE. 383(16), 1544-1555.
- (2020). Model Informed Development of VRC01 in Newborn Infants Using a Population Pharmacokinetics Approach. CLINICAL PHARMACOLOGY & THERAPEUTICS.
- (2020). Convergent Evolution in Breadth of Two V(H)6-1-Encoded Influenza Antibody Clonotypes from a Single Donor. Cell Host & Microbe. 28(3), 434-+.
- (2020). Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality. Science Translational Medicine. 12(547),
- (2020). Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes A Randomized Clinical Trial. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 323(14), 1369-1377.